vs
Side-by-side financial comparison of Donnelley Financial Solutions, Inc. (DFIN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $172.5M, roughly 1.1× Donnelley Financial Solutions, Inc.). On growth, Donnelley Financial Solutions, Inc. posted the faster year-over-year revenue change (10.4% vs 5.1%). Donnelley Financial Solutions, Inc. produced more free cash flow last quarter ($47.9M vs $43.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -7.9%).
Donnelley Financial Solutions (DFIN) is a financial compliance company based in Chicago, Illinois, United States. The company provides software as a service (SaaS) products, software-enabled services (SeS), print, and compliance services related to US Securities and Exchange Commission regulations to companies in capital and investment markets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DFIN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.5M | $196.9M |
| Net Profit | $6.2M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 8.3% | 1.2% |
| Net Margin | 3.6% | — |
| Revenue YoY | 10.4% | 5.1% |
| Net Profit YoY | -1.6% | — |
| EPS (diluted) | $0.31 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.5M | $196.9M | ||
| Q3 25 | $175.3M | $179.5M | ||
| Q2 25 | $218.1M | $181.1M | ||
| Q1 25 | $201.1M | $168.9M | ||
| Q4 24 | $156.3M | $187.3M | ||
| Q3 24 | $179.5M | $168.6M | ||
| Q2 24 | $242.7M | $178.0M | ||
| Q1 24 | $203.4M | $167.1M |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $-40.9M | $5.4M | ||
| Q2 25 | $36.1M | $-4.8M | ||
| Q1 25 | $31.0M | $4.8M | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $8.7M | $-143.5M | ||
| Q2 24 | $44.1M | $18.9M | ||
| Q1 24 | $33.3M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 8.3% | 1.2% | ||
| Q3 25 | 16.1% | 3.5% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 22.8% | 1.2% | ||
| Q4 24 | 6.0% | 13.2% | ||
| Q3 24 | 10.1% | -82.8% | ||
| Q2 24 | 26.6% | 15.9% | ||
| Q1 24 | 21.9% | 7.9% |
| Q4 25 | 3.6% | — | ||
| Q3 25 | -23.3% | 3.0% | ||
| Q2 25 | 16.6% | -2.7% | ||
| Q1 25 | 15.4% | 2.8% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 4.8% | -85.1% | ||
| Q2 24 | 18.2% | 10.6% | ||
| Q1 24 | 16.4% | 5.4% |
| Q4 25 | $0.31 | $0.05 | ||
| Q3 25 | $-1.49 | $0.12 | ||
| Q2 25 | $1.28 | $-0.11 | ||
| Q1 25 | $1.05 | $0.10 | ||
| Q4 24 | $0.21 | $0.38 | ||
| Q3 24 | $0.29 | $-3.11 | ||
| Q2 24 | $1.47 | $0.39 | ||
| Q1 24 | $1.09 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.5M | $238.4M |
| Total DebtLower is stronger | $171.3M | $372.2M |
| Stockholders' EquityBook value | $379.2M | $693.1M |
| Total Assets | $800.4M | $1.3B |
| Debt / EquityLower = less leverage | 0.45× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.5M | $238.4M | ||
| Q3 25 | $22.7M | $246.3M | ||
| Q2 25 | $33.8M | $445.9M | ||
| Q1 25 | $16.2M | $493.6M | ||
| Q4 24 | $57.3M | $484.6M | ||
| Q3 24 | $33.6M | $453.8M | ||
| Q2 24 | $35.0M | $404.2M | ||
| Q1 24 | $43.7M | $325.9M |
| Q4 25 | $171.3M | $372.2M | ||
| Q3 25 | $154.7M | $376.7M | ||
| Q2 25 | $190.1M | $580.5M | ||
| Q1 25 | $189.5M | $583.4M | ||
| Q4 24 | $124.7M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $379.2M | $693.1M | ||
| Q3 25 | $423.1M | $727.2M | ||
| Q2 25 | $432.1M | $757.8M | ||
| Q1 25 | $419.9M | $798.5M | ||
| Q4 24 | $436.1M | $778.3M | ||
| Q3 24 | $444.5M | $749.6M | ||
| Q2 24 | $441.5M | $879.3M | ||
| Q1 24 | $408.9M | $892.2M |
| Q4 25 | $800.4M | $1.3B | ||
| Q3 25 | $816.3M | $1.3B | ||
| Q2 25 | $874.7M | $1.5B | ||
| Q1 25 | $852.8M | $1.6B | ||
| Q4 24 | $841.6M | $1.6B | ||
| Q3 24 | $843.6M | $1.5B | ||
| Q2 24 | $882.9M | $1.6B | ||
| Q1 24 | $867.8M | $1.6B |
| Q4 25 | 0.45× | 0.54× | ||
| Q3 25 | 0.37× | 0.52× | ||
| Q2 25 | 0.44× | 0.77× | ||
| Q1 25 | 0.45× | 0.73× | ||
| Q4 24 | 0.29× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $59.8M | $43.7M |
| Free Cash FlowOCF − Capex | $47.9M | $43.5M |
| FCF MarginFCF / Revenue | 27.8% | 22.1% |
| Capex IntensityCapex / Revenue | 6.9% | 0.1% |
| Cash ConversionOCF / Net Profit | 9.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $107.8M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.8M | $43.7M | ||
| Q3 25 | $74.4M | $60.8M | ||
| Q2 25 | $68.4M | $12.0M | ||
| Q1 25 | $-37.7M | $35.5M | ||
| Q4 24 | $56.4M | $33.1M | ||
| Q3 24 | $86.4M | $53.9M | ||
| Q2 24 | $56.2M | $53.2M | ||
| Q1 24 | $-27.9M | $49.1M |
| Q4 25 | $47.9M | $43.5M | ||
| Q3 25 | $59.2M | $57.0M | ||
| Q2 25 | $51.7M | $9.3M | ||
| Q1 25 | $-51.0M | $26.9M | ||
| Q4 24 | $41.3M | $31.0M | ||
| Q3 24 | $67.3M | $49.8M | ||
| Q2 24 | $36.8M | $51.6M | ||
| Q1 24 | $-40.2M | $46.3M |
| Q4 25 | 27.8% | 22.1% | ||
| Q3 25 | 33.8% | 31.7% | ||
| Q2 25 | 23.7% | 5.1% | ||
| Q1 25 | -25.4% | 15.9% | ||
| Q4 24 | 26.4% | 16.6% | ||
| Q3 24 | 37.5% | 29.6% | ||
| Q2 24 | 15.2% | 29.0% | ||
| Q1 24 | -19.8% | 27.7% |
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 8.7% | 2.2% | ||
| Q2 25 | 7.7% | 1.5% | ||
| Q1 25 | 6.6% | 5.1% | ||
| Q4 24 | 9.7% | 1.1% | ||
| Q3 24 | 10.6% | 2.4% | ||
| Q2 24 | 8.0% | 0.9% | ||
| Q1 24 | 6.0% | 1.7% |
| Q4 25 | 9.65× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 1.89× | — | ||
| Q1 25 | -1.22× | 7.37× | ||
| Q4 24 | 8.95× | — | ||
| Q3 24 | 9.93× | — | ||
| Q2 24 | 1.27× | 2.82× | ||
| Q1 24 | -0.84× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
